Status:
TERMINATED
FLX475 in Combination With Ipilimumab in Advanced Melanoma
Lead Sponsor:
RAPT Therapeutics, Inc.
Conditions:
Advanced Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This clinical trial is a Phase 2, open-label study to determine the anti-tumor activity of FLX475 in combination with ipilimumab in subjects with advanced melanoma previously treated with an anti-prog...
Eligibility Criteria
Inclusion
- Stage IV or unresectable Stage III advanced melanoma
- Prior treatment with at least 2 months of anti-PD-(L)1 agent
- Measurable disease at baseline
- Tumor available for biopsy
Exclusion
- History of allergy or severe hypersensitivity to biologic agents
- History of Grade 3-4 immune-related adverse events leading to discontinuation of prior immunotherapy
- Prior treatment with ipilimumab or other (cytotoxic T-lymphocyte-associated antigen 4) CTLA-4 antagonists
Key Trial Info
Start Date :
September 3 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 13 2022
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT04894994
Start Date
September 3 2021
End Date
September 13 2022
Last Update
December 5 2023
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Los Angeles
Los Angeles, California, United States, 90095
2
Moffitt Cancer Center
Tampa, Florida, United States, 33612
3
Washington University School of Medicine St. Louis
St Louis, Missouri, United States, 63110
4
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030